W e have examined the amino acid transport in B cell chronic lymphocytic leukemia and compared it with the amino acid transport in isolated B lymphocytes from human blood and tonsils. L-system transport was measured with 2-amino-2-carboxy-bicyclo (2,2,1)-heptane, which is a synthetic amino acid whose transport is limited to the L-system. Amino acid uptake was subjected to a multicomponent analysis that partitioned the total uptake into the saturable carrier-mediated transport system and the uptake by diffusion. The maximal velocity of L-system transport in chronic lymphocytic leukemia cells, 81 mumol/1 cell water per min, was less than 10% that of blood B lymphocytes, which was 1,029 mumol/1 cell water per min. The uptake of 2-amino-2-carboxy-bicyclo (2,2,1)-heptane by tonsillar B cells, by a B lymphocyte cell line, and by blood T-lymphocytes was also 10-fold greater than that observed in chronic lymphocytic leukemic cells. Similarly, the L-system uptake of leucine and phenylalanine, which are naturally occurring amino acids usually transported primarily by the L-system, was reduced in chronic lymphocytic leukemic B cells to 15 and 10% of normal B cells, respectively. Total leucine uptake by chronic lymphocytic leukemic cells, however, was sustained at 30% of that expected because of transport via an alternative transport system. The A- or ASC-systems, the other major amino acid transport pathways, were not defective in chronic lymphocytic leukemic cells. These data indicate that there is a specific, profound decrease in L-system carrier-mediated amino acid transport in chronic lymphocytic leukemic B cells, as judged by the system-specific synthetic amino acid, 2-amino-2-carboxy-bicyclo (2,2,1)-heptane. This defect was confirmed by studies with two naturally occurring L-system amino acids, leucine and phenylalanine. This specific abnormality of membrane transport by chronic lymphocytic leukemic B lymphocytes is not shared by other B lymphocyte types, and thus appears to be related to the neoplastic nature of the leukemic B cells rather than to their immunologic subtype.